Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 1;5(1):30.
doi: 10.1038/s41392-020-0143-9.

Inhibition of USP14 and UCH37 deubiquitinating activity by b-AP15 as a potential therapy for tumors with p53 deficiency

Yu-Shui Ma #  1   2   3   4 , Xiao-Feng Wang #  5 , Fei Yu #  3 , Ting-Miao Wu #  4 , Ji-Bin Liu #  2 , Yun-Jie Zhang  5 , Qing Xia  5 , Zong-Yuan Jiang  6 , Qin-Lu Lin  7 , Da Fu  8   9   10
Affiliations

Inhibition of USP14 and UCH37 deubiquitinating activity by b-AP15 as a potential therapy for tumors with p53 deficiency

Yu-Shui Ma et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
b-AP15 resulted in durable tumor regressions in p53-deficient mice. a Kaplan–Meier survival analysis was used to evaluate the treatment effect of b-AP15 in WT and heterozygous p53+/− mice for OS. b X-ray, micro-CT, and MRI analysis and type of primary tumors in p53-deficient mice. The effect of b-AP15 in WT and heterozygous p53+/− mice on the number of types of cancer was quantified. H&E staining analysis (c) and IHC staining for p53 (d) of normal or primary tumors in the bone, soft tissue, and thymus in WT or p53-deficient mice with or without treatment of b-AP15. e WB was used to measure the effect of b-AP15 on the protein level of cell cycle-, senescent-, and apoptosis-associated markers in heterozygous p53+/− mice. Ctrl control, MLT malignant lymphomas of thymus, NA not applicable, OSA osteosarcoma, STS soft tissue sarcoma, WT wild type
See this image and copyright information in PMC

References

    1. Mastropasqua F, et al. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. Mol. Cancer. 2017;16:67. doi: 10.1186/s12943-017-0634-7. - DOI - PMC - PubMed
    1. Mancini F, et al. MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. Mol. Cancer. 2017;16:55. doi: 10.1186/s12943-017-0626-7. - DOI - PMC - PubMed
    1. Jacks T, et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994;4:1–7. doi: 10.1016/S0960-9822(00)00002-6. - DOI - PubMed
    1. D’Arcy P, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 2011;17:1636–1640. doi: 10.1038/nm.2536. - DOI - PubMed
    1. Husnjak K, et al. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature. 2008;453:481–488. doi: 10.1038/nature06926. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances